{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:45:27Z","timestamp":1775306727630,"version":"3.50.1"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.1717","type":"journal-article","created":{"date-parts":[[2014,5,31]],"date-time":"2014-05-31T23:22:11Z","timestamp":1401578531000},"page":"1201-1204","source":"Crossref","is-referenced-by-count":7,"title":["Neuroleptic Malignant Syndrome Induced by Combination Therapy with Tetrabenazine and Tiapride in a Japanese Patient with Huntington's Disease at the Terminal Stage of Recurrent Breast Cancer"],"prefix":"10.2169","volume":"53","author":[{"given":"Ichiro","family":"Nozaki","sequence":"first","affiliation":[{"name":"Department of Neurology, National Hospital Organization Iou National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kouseiren Takaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kato-Motozaki","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Iou National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokuhei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Iou National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuro","family":"Tagami","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Hospital Organization Iou National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Iou National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiho","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Iou National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyonobu","family":"Komai","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Iou National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Harper PS. The epidemiology of Huntington's disease. Hum Genet 89: 365-376, 1992.","DOI":"10.1007\/BF00194305"},{"key":"2","unstructured":"2. Scott LJ. Tetrabenazine: for chorea associated with Huntington's disease. CNS Drugs 25: 1073-1085, 2011."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 31: 1022-1025, 1981.","DOI":"10.1212\/WNL.31.8.1022"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mateo D, Muñoz-Blanco JL, Giménez-Roldán S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin Neuropharmacol 15: 63-68, 1992.","DOI":"10.1097\/00002826-199202000-00009"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord 11: 95, 1996.","DOI":"10.1002\/mds.870110118"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord 12: 246-248, 1997.","DOI":"10.1002\/mds.870120219"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 142: 1137-1145, 1985.","DOI":"10.1176\/ajp.142.10.1137"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143: 1227-1233, 1986.","DOI":"10.1176\/ajp.143.10.1227"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 77: 185-202, 1993.","DOI":"10.1016\/S0025-7125(16)30278-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kawanishi C, Onishi H, Kato D, Yamada T, Onose M, Hirayasu Y. Neuroleptic malignant syndrome in cancer treatment. Palliat Support Care 3: 51-53, 2005.","DOI":"10.1017\/S147895150505008X"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Stevens E, Roman A, Houa M, Razavi D, Jaspar N. Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia. Intensive Care Med 24: 369-371, 1998.","DOI":"10.1007\/s001340050583"},{"key":"12","unstructured":"12. Hermesh H, Huberman M, Radvan H, Kott E. Recurrent neuroleptic malignant syndrome due to tiapride and haloperidol: the possible role of D-2 dopamine receptors. J Nerv Ment Dis 172: 692-695, 1984."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Duarte J, Campos JM, Cabezas C, Sagredo V, Cortina J, Claveria LE. Neuroleptic malignant syndrome while on tiapride treatment. Clin Neuropharmacol 19: 539-540, 1996.","DOI":"10.1097\/00002826-199619060-00010"},{"key":"14","unstructured":"14. Noda S. Delayed type malignant syndrome and Parkinson's syndrome due to tiapride, Reye-like syndrome induced by calcium hopantenate. Ryoikibetsu Shokogun Series 27: 538-541, 1997 (in Japanese)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Amore M, Zazzeri N. Neuroleptic malignant syndrome after neuroleptic discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 19: 1323-1334, 1995.","DOI":"10.1016\/0278-5846(95)00269-3"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/11\/53_53.1717\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:51:13Z","timestamp":1621446673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/11\/53_53.1717\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.1717","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}